Clinical glycoproteomics and artificial intelligence
A powerful new tool for precision medicine
InterVenn Biosciences has developed a proprietary glycoproteomic platform based on AI and mass spectrometry for the discovery of novel glycoproteomic biomarkers and their application to next-gen precision medicine.
The company is working to find new solutions in a range of oncology indications, along with making its Vista suite of solutions available to its partners for advanced life-science R&D applications.
InterVenn’s VISTATM is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.